14 November 2024
14 November 2024 Aviva plc Q3 2024 Trading Update Aviva plc’s Q3 Trading Update for the nine-month period ended 30 September 2024 is available…
13 November 2024
Strong execution drives good growth in H1 7am, 13 November 2024 ─ Experian plc, the global data and technology company, today issues its financial report…
SSE PLC: interim resultsfor six months ended 30 September 2024 13 November 2024 DELIVERING MISSION CRITICAL INVESTMENT · Strong start to financial year, delivering adjusted…
12 November 2024
12 November 2024 AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States AstraZeneca today announces $3.5 billion of capital investment in…
12 November 2024 Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase…
8 November 2024
Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps Tezspire demonstrated a statistically significant and…
31 October 2024
SUMMARY OF UNAUDITED RESULTS Quarters $ million Nine months Q3 2024 Q2 2024 Q3 2023 %¹ Reference 2024 2023 % 4,291 …
30 October 2024
GSK on track to deliver 2024 outlooks with further good progress made in R&D Q3 2024 sales and core earnings growth driven by strong…